CDK9 and mantle cell lymphoma: Although the CDK9 selective inhibitors A‐1467729 and A‐1592668 had mild single‐agent activity in MCL cell lines and primary patient samples, broad synergy with venetoclax was observed across all MCL cell systems studied that was related to the loss in RNApoll‐II phosphorylation and the concomitant reduction in MCL‐1 protein levels.